Rozanne Wilson and her co-authors talk about the “call to action” to elevate the critical components of Patient-Centered Decision-Making and what that looks like in this month’s JNCCN article.
While statins have transformed cardiovascular disease prevention, patients with a lesser-known type of lipid disease called elevated lipoprotein(a) (Lp[a]) face unique challenges. Recent clinical trials exploring Lp(a)-targeting medications show promise, yet proactive screening practices vary. Cynthia Miller, MD, MPH, FACP, Vice President, Medical Director, sits down with DocWire News and shares insights on the significance of early Lp(a) screening, strategies to enhance preventative cardiology, and optimize patient care.
The Inflation Reduction Act will increase drug affordability—but that money comes from somewhere. Ryan Cox, VP, Director, PRECISIONvalue Access Experience Team, discusses the unintended consequences for payers, biopharmaceuticals—and the future of patient’s drug choices. Learn more in this video.
The PV&H March Events Calendar is here! Get all the details on Precision at upcoming conferences, links to upcoming and on-demand webinars, and catch up on our latest thought leadership!
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
The rules of engagement for patient and caregiver communities have changed. Once off limit to industry insiders, patient communities are now opening their doors to pharma. What does this mean for pharma companies and how do you shift your strategy? Jack DeManche, Director of Digital Strategy at PRECISIONeffect, chats with MM+M and other industry leaders about the catalysts driving the shift towards greater community engagement, insights into the evolving landscape of patient involvement, and nuanced approaches to fostering collaborations.
In Part 2, Maureen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, dive deeper into Navigating Health Equity in 2024, focusing on the significance of accreditations in addressing health disparities and promoting health equity, highlighting programs for achieving accreditation and advocating for the integration of social determinants of health (SDOH) and health equity practices within pharmacy and health care.
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Register for a free trial subscription and read the article HERE!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
